{"id":"NCT02767765","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy","officialTitle":"Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormonÂ® - at High Dose in Anemic Cancer Patients Treated With Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2006-10","completion":"2006-10","firstPosted":"2016-05-10","resultsPosted":"2017-04-04","lastUpdate":"2017-04-04"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"r-HuEPO","otherNames":["NeoRecormon"]}],"arms":[{"label":"r-HuEPO","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.","primaryOutcome":{"measure":"Percentage of Participants With Response to Treatment","timeFrame":"Week 4","effectByArm":[{"arm":"r-HuEPO","deltaMin":50.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":7,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":61},"commonTop":["Anaemia","Abdominal pain","Gastric ulcer haemorrhage","Asthenia","Oedema peripheral"]}}